|
6 Companies |
|
13 Products |
|
13 Products |
|
33 Mechanisms of Action |
|
0 Trials |
|
19 News |
|
- Enrollment change, Trial withdrawal: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Basel, Switzerland
N=200 --> 0 | Active, not recruiting --> Withdrawn
- |||| trebananib (AMG 386) / Amgen
Trial completion, Combination therapy, Metastases: AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib (clinicaltrials.gov) - Feb 10, 2015
P2, N=152, Completed, Sponsor: Amgen
N=200 --> 0 | Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: High-dose Bevacizumab in Advanced Renal Carcinoma Patients (clinicaltrials.gov) - Dec 22, 2014
P2, N=119, Completed, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2013
- | Anyara (naptumomab estafenatox) / NeoTX
Trial completion, Metastases: ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer (clinicaltrials.gov) - Aug 25, 2014
P1, N=44, Completed, Sponsor: Active Biotech AB
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jul 2013 No longer recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial completion, Surgery: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (clinicaltrials.gov) - Jun 26, 2014
P2, N=34, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||| Roferon A (recombinant interferon alfa-2a) / Roche, Avastin (bevacizumab) / Roche
Enrollment change, Metastases: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=467, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=364 --> 467
- | thalidomide / Generic mfg.
Trial completion: Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: National Cancer Institute (NCI)
N=364 --> 467 Active, not recruiting --> Completed
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer (clinicaltrials.gov) - Jan 7, 2014
P2, N=34, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Trial completion, Surgery: Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer (clinicaltrials.gov) - Dec 16, 2013
P3, N=2300, Completed, Sponsor: Medical Research Council
Completed --> Active, not recruiting Active, not recruiting --> Completed
- | cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Trial completion: Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer (clinicaltrials.gov) - Jul 31, 2013
P3, N=400, Completed, Sponsor: Nordic Society for Gynaecologic Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Roferon A (recombinant interferon alfa-2a) / Roche, Avastin (bevacizumab) / Roche
Trial completion, Metastases: Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer (clinicaltrials.gov) - May 9, 2013
P2, N=467, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Sutent (sunitinib) / Pfizer
New P2 trial: Sunitinib (clinicaltrials.gov) - Apr 3, 2013
P2, N=30, Recruiting, Sponsor: Cathay General Hospital
- cisplatin / Generic mfg.
Enrollment change, Surgery, Metastases: Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - Oct 15, 2012
P1, N=12, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
Active, not recruiting --> Completed N=30 --> 12
- cisplatin / Generic mfg.
Trial completion, Surgery, Metastases: Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - Oct 15, 2012
P1, N=12, Completed, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
N=30 --> 12 Active, not recruiting --> Completed
- carboplatin / Generic mfg., amifostine / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2012
P2, N=57, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- celecoxib oral / Generic mfg.
Trial termination: A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers (clinicaltrials.gov) - Apr 21, 2012
P2, N=23, Terminated, Sponsor: Mark H. Einstein
Active, not recruiting --> Completed Suspended --> Terminated; Due to reported toxicity of Celecoxib at high doses
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: High-dose Bevacizumab in Advanced Renal Carcinoma Patients (clinicaltrials.gov) - Jan 3, 2012
P2, N=120, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Suspended --> Terminated; Due to reported toxicity of Celecoxib at high doses Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer (clinicaltrials.gov) - Sep 26, 2011
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed